MediXin is a cross-border healthcare advisory and execution firm. We support global healthcare companies in entering China, and China-based companies in expanding internationally — from strategy to execution.
With deep expertise in China's healthcare policy, regulatory systems, and market access, MediXin translates complex environments into actionable pathways and ensures delivery through strong execution capability.
Our work focuses on enabling cross-border healthcare innovation, with particular strength in navigating China's regulatory landscape and supporting execution across Hong Kong, the Greater Bay Area, and global markets.
Kang Wei | 康韦
Kang Wei is the Founder and Strategic Lead of MediXin Group. She brings a unique combination of policy leadership, industry expertise, and execution capability.
From Policy Leadership to Execution
Former Managing Director of RDPAC. Worked closely with multinational companies and regulatory authorities.
Building Innovation Ecosystems
Founder of Greater Bay Area Alliance of Pharmaceutical Innovation (GBAAPI), connecting regulators, industry leaders, and global stakeholders.
From Strategy to Execution
Supports global healthcare companies entering China and China-based innovation expanding globally. We do not stop at strategy — we deliver results.
Industry Experience
Vice President, Fresenius Kabi China | Senior Marketing Director & BU Head, Novartis Greater China
Annette Chiu | 赵碧琴
Annette Chiu is a highly experienced regulatory expert with over 30 years of experience across Hong Kong, China, and the Greater Bay Area. She has successfully led and accelerated the registration of more than 20 innovative products, including NCEs, biologics, and vaccines. She has extensive experience in regulatory strategy, pharmacovigilance, and GMP compliance, and has supported CFDI GMP inspections in China. Her therapeutic experience spans oncology, infectious diseases, vaccines, and chronic diseases. She also brings strong expertise in market entry strategy and engagement with regulatory authorities.
James Zhu | 祝志强
Dr. James Zhu brings over 30 years of experience in multinational pharmaceutical companies, having served as Head of Medical Affairs at Takeda Pharmaceuticals Hong Kong and as a Board Member of HKAPI. He has deep expertise in regulatory strategy, medical affairs leadership, KOL engagement, evidence generation, and Greater Bay Area market access — particularly under the Hong Kong "1+" mechanism. He currently serves as Executive Director at NovoBay Biotechnology (Hong Kong) and supports MediXin clients as a Medical Affairs Partner.